King of Prussia, Pennsylvania — February 19, 2026 — Leads & Copy — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, has announced leadership appointments as it prepares for regulatory discussions and clinical milestones for its drug candidates PH-762 and PH-894.
Lisa Carson has been promoted to Chief Financial Officer, and Jennifer Phillips, Pharm.D., has been named Senior Vice President, Regulatory and Corporate Affairs. Kimberly Man has joined the company as Vice President of Program Development and Strategic Planning, reporting to President and Chief Executive Officer Robert Bitterman.
According to Bitterman, these appointments strengthen the company’s finance and regulatory leadership as PH-762 advances. The company’s focus is on achieving the next set of milestones with discipline and consistency.
Carson, who joined Phio in May 2025, will oversee financial operations, capital planning, and financial reporting. She previously served as Vice President, Finance and Controller at Prelude Therapeutics, where she supported the company’s IPO and subsequent expansion, and held finance leadership roles at TELA Bio and PhaseBio Pharmaceuticals.
Phillips, who joined Phio in February 2023, will lead regulatory strategy and agency engagement. She has more than 25 years of regulatory affairs experience, including senior roles at Aventis, Wyeth, and Cutanea Life Sciences.
Man will lead program coordination for PH-762 and support program work on PH-894. She has over 20 years of experience in program and portfolio leadership, product development, and clinical and regulatory operations, with previous roles at Sandoz and Cutanea Life Sciences.
Phio Pharmaceuticals is focused on advancing its INTASYL® siRNA gene silencing technology to eliminate cancer. Its lead clinical development program is PH-762, an INTASYL compound that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
Source: Phio Pharmaceuticals Corp.
